Who actually earns your trust for compounded GLP-1?

Each provider ran through the same five-part rubric — pricing transparency, pharmacy disclosure, reviews, clinical oversight, and support — detailed in our methodology. Some links here are affiliate links, but compensation does not change a provider's score.

No. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. They're prepared by U.S.-licensed compounding pharmacies when a licensed provider determines treatment is appropriate. Compounded semaglutide is not Ozempic® or Wegovy®; compounded tirzepatide is not Mounjaro® or Zepbound®.

Because compounded drugs aren't FDA-approved, the pharmacy is the main quality signal. Providers that name their pharmacy and can supply a certificate of analysis (potency, sterility) let you verify what you're injecting. Several providers reviewed here don't publicly name their current pharmacy.

Across the providers here, semaglutide runs from roughly $99 to $299 per month, though several add a separate membership (Mochi, Ivim, Zealthy) and some gate the real number behind an intake form. Figures were sourced in mid-2026 and change frequently; confirm on each provider's own site.

The rules tightened. After the FDA declared the semaglutide and tirzepatide shortages resolved in 2025, the broad shortage-era allowance for mass compounding of these drugs ended. Compounding is now generally limited to specific, documented individual situations a licensed prescriber signs off on — for example a verified allergy to an inactive ingredient or a medically necessary non-standard formulation — rather than routine cost savings or preference. The FDA also warned telehealth marketers in 2025 about how compounded GLP-1s are advertised. A legitimate provider should assess whether you actually qualify. This is general information, not legal or medical advice; confirm your own situation with a licensed clinician.

Because compounded drugs aren't FDA-reviewed, their quality, potency, and sterility depend entirely on the compounding pharmacy — there's no federal guarantee. The FDA has logged adverse-event reports linked to compounded GLP-1s, including problems from dosing errors with self-measured or non-standard preparations. That's why we weight pharmacy transparency so heavily: a named pharmacy that can provide a certificate of analysis is a real safety signal. Discuss the risks with a licensed clinician before starting.

A legitimate provider requires a genuine medical evaluation by a clinician licensed in your state, screens your history for contraindications, and never ships medication with no consultation at all. Naming the compounding pharmacy and offering testing documentation are strong positive signals. The clearest red flag is a site that will sell you a GLP-1 with no intake and no clinician involved.

Insurance generally does not cover compounded medication, so you pay cash. If cost is the real issue, it's worth pricing the brand: eligible commercial-insurance patients can pay as little as about $25/month for Zepbound® or Mounjaro® with the manufacturer savings card, and a Medicare pilot starting July 2026 offers some beneficiaries a flat $50/month for certain weight-loss drugs. Brand list prices without any coverage are much higher (often $500 to $1,000+ a month). Verify your own coverage and eligibility directly.

Brand-name semaglutide and tirzepatide are FDA-approved and carry manufacturer quality oversight; compounded versions are neither. They share an active ingredient but are not considered interchangeable. Cash-pay compounded is usually cheaper up front, while brand can end up cheaper with insurance or savings programs and comes with the FDA assurance compounded lacks. Which makes sense depends on your coverage, your budget, and your clinician's guidance.

For the same molecule, compounded and brand use the same milligram doses and the same titration ladder, so a prescriber can usually manage that switch. Moving between semaglutide and tirzepatide is different — they're separate molecules, so it means starting a new titration schedule, not a one-to-one dose swap. Do any switch under a clinician's supervision.

It's unclear. Some programs sell oral, sublingual, or "microdose" compounded GLP-1, but those forms haven't been well studied in people, so how much medication actually absorbs — and how well it works — isn't established. Injectable forms have far more real-world track record. Treat non-injectable compounded formats with extra caution and ask the provider what evidence supports them.

Cancellation and refund friction is one of the most common complaints across telehealth GLP-1 programs — auto-renewals, prepaid multi-month plans, and non-refundable fees. Before you enroll, read the cancellation terms and check whether prepaid plans are refundable. We note each provider's guarantee and refund posture in its scorecard.